Morten Uthaug

Clinical Researcher in Psychopharmacology

Data updated

Papers

15 publications

Trials

0 clinical trials

Research Footprint

Morten Uthaug appears in 15 tracked papers (2018–2025), most studied alongside Ayahuasca, 5-MeO-DMT and Mescaline, across Anxiety Disorders, Depressive Disorders and Creativity.

Most-cited paper: Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution (213 citations).

Frequent co-authors: Johannes Ramaekers, Nathalie Mason and Kim Kuypers.

Background & Research

Morten Uthaug is a Norwegian clinical researcher whose work sits at the intersection of psychopharmacology, clinical observation and psychedelic epidemiology. He has produced a series of naturalistic studies and analyses examining the psychological effects of a range of entheogens — including 5‑MeO‑DMT vapor from toad secretion, psilocybin in retreat settings, San Pedro (Echinopsis pachanoi) ceremonial use and ayahuasca — and has contributed to population‑level surveys of classic psychedelic use. His research emphasizes real‑world contexts, phenomenological characterisation of altered states, and short‑acting psychedelic compounds as models for fundamental changes in consciousness.

Uthaug’s publications and collaborative projects have also engaged clinical‑pharmacological questions (notably concerning ultra‑short acting tryptamines), ethical considerations in contemporary psychedelic research, and methodological approaches to observational studies and internet‑based epidemiology. He is known for bridging naturalistic fieldwork with controlled pharmacological thinking, contributing to the evidence base on safety, subjective outcomes (for example changes in anxiety, well‑being and mindfulness capacities), and the potential translational applications of rapidly acting psychedelic compounds.

Affiliations

Institutions, companies, and organisations Morten Uthaug is associated with.